Report
Pedro Echeguren
EUR 10.00 For Business Accounts Only

Almirall: Issues €250mn in convertible bonds

Almirall: Issues €250mn in convertible bonds

  • Refinances the Allergan acquisition with a convertible bond and a syndicated loan
  • We expect a 2% dilution
  • Allergan: a quantum leap
  • New products
  • New target price €15.82. Buy (from Hold)
Underlying
Almirall SA

Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.

Provider
Bankinter S.A.
Bankinter S.A.

Bankinter S.A. is a Spanish brokerage firm established in 1989. The company's line of business includes the provision of market research and trading services for Equity and Fixed Income products.

Analysts
Pedro Echeguren

Other Reports on these Companies
Other Reports from Bankinter S.A.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch